Compare TSAT & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSAT | NBP |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | Canada | United States |
| Employees | 711 | 32 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.5M | 379.3M |
| IPO Year | 2021 | N/A |
| Metric | TSAT | NBP |
|---|---|---|
| Price | $50.70 | $2.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $37.00 | $9.00 |
| AVG Volume (30 Days) | 172.2K | ★ 860.5K |
| Earning Date | 05-05-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.81 | $2.10 |
| 52 Week High | $47.90 | $5.19 |
| Indicator | TSAT | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 71.13 | 49.72 |
| Support Level | $22.04 | $2.19 |
| Resistance Level | N/A | $3.80 |
| Average True Range (ATR) | 3.55 | 0.21 |
| MACD | 0.74 | 0.05 |
| Stochastic Oscillator | 94.13 | 83.09 |
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.